Patients and Methods
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Cancer statistics.CA: Cancer J Clin. 2018; 68 (2018): 7-30https://doi.org/10.3322/caac.21442
- Recent trends in the age at diagnosis of colorectal cancer in the US National Cancer Data Base, 2004-2015.Cancer. 2019; 125: 3828-3835https://doi.org/10.1002/cncr.32347
- Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement.JAMA. 2021; 325: 1965-1977https://doi.org/10.1001/jama.2021.6238
- Role of DNA mismatch repair defects in the pathogenesis of human cancer.J Clin Oncol. 2003; 21: 1174-1179https://doi.org/10.1200/JCO.2003.04.060
Benson AB, Venook AP, Al-Hawary MM. NCCN Guidelines for Colon Cancer. Version 2.2018. doi: 10.6004/jnccn.2018.0021.
- Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.J Clin Oncol. 2010; 28: 3219https://doi.org/10.1200/JCO.2009.27.1825
Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017;18(9):1182-91. doi: 10.1016/S1470-2045(17)30422-9.
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science. 2017; 357: 409-413https://doi.org/10.1126/science.aan6733
- Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.J Clin Oncol. 2018; 36: 773-779https://doi.org/10.1200/JCO.2017.76.9901
- Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis.Familial Cancer. 2016; 15: 253-260https://doi.org/10.1007/s10689-015-9856-2
- Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis.J Clin Oncol. 2015; 33: 2084https://doi.org/10.1200/JCO.2014.59.3665
- Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium.Eur J Cancer. 2014; 50: 987-996https://doi.org/10.1016/j.ejca.2013.12.005
- Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.Am J Clin Pathol. 2017; 147: 221-260https://doi.org/10.1200/JCO.2016.71.9807
- Impact of age and mismatch repair status on survival in colorectal cancer.Cancer Med-us. 2017; 6: 975-981https://doi.org/10.1371/journal.pone.0172799
- Evaluation of yield and experiences of age-related molecular investigation for heritable and nonheritable causes of mismatch repair deficient colorectal cancer to identify Lynch syndrome.Int J Cancer. 2020; 147: 2150-2158https://doi.org/10.1002/ijc.33117
- Real-world outcome of universal screening for Lynch syndrome in Japanese patients with colorectal cancer highlights the importance of targeting patients with young-onset disease.Mol Clin Oncol. 2021; 15: 247https://doi.org/10.3892/mco.2021.2409
- Early-onset colorectal cancer: a sporadic or inherited disease?.World J Gastroenterol. 2014; 20: 12420https://doi.org/10.3748/wjg.v20.i35.12420
- Characteristics of BRAFV600E mutant, deficient mismatch repair/proficient mismatch repair, metastatic colorectal cancer: a multicenter series of 287 patients.Oncologist. 2019; 24: e1331-e1340https://doi.org/10.1634/theoncologist.2018-0914
- National trends in colorectal cancer incidence among older and younger adults in Canada.JAMA Netw Open. 2019; 2 (e198090-e)https://doi.org/10.1001/jamanetworkopen.2019.8090